|
시장보고서
상품코드
2038141
데가렐릭스(Degarelix) 시장 규모 : 적응증별, 제형별, 유통 채널별, 지역별 및 예측별Global Degarelix Market Size By Indication (Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, Hormone-Sensitive Prostate Cancer), By Dosage Form, By Distribution Channel By Geographic Scope And Forecast |
||||||
세계 데가렐릭스 시장 분석
Verified Market Research에 따르면, 세계 디갈릭스 시장 규모는 2025년에 12억 달러로 평가되었고, 2033년까지 25억 달러에 달할 것으로 예상되며, 2027-2033년 연평균 9.0%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.
데가렐릭스 시장은 특히 전립선암 치료에 초점을 맞추고 있는 제약업계의 신흥 분야입니다. 데갈렐릭스는 성선자극호르몬 방출 호르몬(GnRH) 길항제로, 환자의 테스토스테론 수치를 빠르게 감소시켜 진행성 전립선암 관리에 중요한 역할을 하고 있습니다. 특히 전립선암의 유병률이 지속적으로 증가하고 있는 가운데, 그 효과와 비교적 빠른 작용 발현이 주목받고 있습니다.
세계 데가렐릭스 시장의 정의
데갈렐릭스 시장은 주로 진행성 전립선암 치료에 사용되는 성선자극호르몬 방출 호르몬(GnRH) 수용체 길항제인 데갈렐릭스의 제조, 유통 및 임상적 사용을 둘러싼 세계 시장 상황을 말합니다. 데갈렐릭스는 뇌하수체 내 GnRH 수용체를 직접 차단하여 작용하며, GnRH 작용제에서 흔히 볼 수 있는 초기 테스토스테론 급증을 유발하지 않고 테스토스테론 수치를 빠르게 떨어뜨립니다. 이러한 작용기전으로 인해 테스토스테론의 감소가 종양의 성장을 늦추거나 막는 데 도움이 되는 호르몬 민감성 전립선암 관리에 특히 유용합니다. 이 시장에는 Firmagon(필마곤)과 같은 브랜드 제제뿐만 아니라 향후 제네릭 의약품 및 바이오시밀러 개발, 그리고 병원, 종양학 클리닉, 전문 약국 등 관련 유통 채널이 포함됩니다.
데가렐릭스 시장의 성장은 전 세계 전립선암 유병률 증가, 안드로겐 차단 요법(ADT)의 채택 확대, 종양 치료 프로토콜의 발전에 힘입어 성장하고 있습니다. 의료진은 GnRH 작용제에 비해 테스토스테론을 빠르게 억제하고 종양 발화 위험이 낮기 때문에 특정 임상 상황에서 데가렐릭스를 선호하고 있습니다. 이 시장 생태계에는 제약사, 위탁생산업체(CMO), 의료진, 그리고 의약품의 승인, 가격 책정, 상환에 영향을 미치는 규제 당국이 포함됩니다. 또한, 개선된 제형, 서방형 주사제 및 병용요법에 대한 지속적인 연구는 북미, 유럽, 아시아태평양 등 주요 지역의 데가렐릭스 시장의 경쟁 환경과 향후 시장 확대를 형성하고 있습니다.
세계 데가렐릭스 시장 개요
데가렐릭스 시장은 주로 전 세계 전립선암 유병률 증가와 호르몬 민감성 및 진행성 전립선암의 표준 치료로서 안드로겐 차단 요법(ADT)의 채택 확대에 의해 주도되고 있습니다. 데가렐릭스는 전립선 종양의 성장과 진행에 중요한 역할을 하는 테스토스테론 수치를 억제하는 데 사용되는 성선자극호르몬 방출 호르몬(GnRH) 수용체 길항제입니다. 이 약은 뇌하수체 내 GnRH 수용체를 직접 차단하여 황체형성호르몬(LH)과 난포자극호르몬(FSH)을 빠르게 감소시키고, 테스토스테론 생성을 신속하고 지속적으로 감소시켜 암의 진행을 지연시킵니다.
전립선암 치료에 사용되는 기존 GnRH 작용제와 비교했을 때, 데가렐릭스는 임상적 이점이 있기 때문에 시장에서 수요가 증가하고 있습니다. GnRH 작용제와 달리 데갈렐릭스는 초기 테스토스테론 급증(일명 '종양 플레어'라고도 함)을 유발하지 않기 때문에 진행성 암 환자의 증상 악화를 예방할 수 있습니다. 이러한 빠른 테스토스테론 억제 효과로 인해 데가렐릭스는 호르몬 치료 요법에서 중요한 치료 옵션이 되었으며, 특히 전이성 또는 진행성 호르몬 의존성 전립선암 환자들에게 중요한 치료 옵션이 되었습니다. 전립선특이항원(PSA) 수치를 낮추고 질병 진행을 지연시키는 효과로 인해 임상 현장에서의 사용 확대가 더욱 가속화되고 있습니다.
또한, 암 조기 진단에 대한 인식 제고, 종양 치료 인프라 확충, 호르몬 요법에 대한 지속적인 연구 등이 데가렐릭스 시장 확대에 기여하고 있습니다. 제약사들은 또한 제형 개선, 투여 요법 최적화, 신흥 헬스케어 시장에서의 접근성 확대에 초점을 맞추었습니다. 그러나 시장에서는 새로운 경구용 GnRH 길항제 및 기존 LHRH 작용제를 포함한 다른 안드로겐 차단 요법과 경쟁에 직면해 있으며, 이는 치료법 선택에 영향을 미칠 수 있습니다. 이러한 과제에도 불구하고 전립선암 치료제의 지속적인 발전과 효과적인 호르몬 억제 요법에 대한 수요 증가는 향후 몇 년 동안 꾸준한 시장 성장을 뒷받침할 것으로 예측됩니다.
Global Degarelix Market Analysis
According to Verified Market Research, the Global Degarelix Market size was valued at USD 1.2 Billion in 2025 and is estimated to reach USD 2.5 Billion by 2033, growing at a CAGR of 9.0% from 2027 to 2033.
The Degarelix market is an emerging segment within the pharmaceutical industry, specifically focused on treatments for prostate cancer. Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist that plays a crucial role in managing advanced prostate cancer by rapidly reducing testosterone levels in patients. Its effectiveness and relatively quick onset of action have gaered attention, particularly as the prevalence of prostate cancer continues to rise.
Global Degarelix Market Definition
The Degarelix market refers to the global commercial landscape surrounding the production, distribution, and clinical use of degarelix, a gonadotropin-releasing hormone (GnRH) receptor antagonist primarily used in the treatment of advanced prostate cancer. Degarelix works by directly blocking GnRH receptors in the pituitary gland, leading to a rapid reduction in testosterone levels without causing the initial testosterone surge commonly associated with GnRH agonists. This mechanism makes it particularly valuable in managing hormone-sensitive prostate cancer, where lowering testosterone helps slow or stop tumor growth. The market includes branded formulations such as Firmagon, as well as potential generic or biosimilar developments, along with related distribution channels including hospitals, oncology clinics, and specialty pharmacies.
The growth of the degarelix market is driven by the increasing global prevalence of Prostate Cancer, rising adoption of androgen deprivation therapy (ADT), and advancements in oncology treatment protocols. Healthcare providers prefer degarelix in certain clinical scenarios due to its rapid testosterone suppression and lower risk of tumor flare compared with GnRH agonists. The market ecosystem encompasses pharmaceutical manufacturers, contract manufacturing organizations, healthcare providers, and regulatory bodies that influence drug approval, pricing, and reimbursement. Additionally, ongoing research into improved formulations, extended-release injections, and combination therapies is shaping the competitive landscape and future expansion of the degarelix market across major regions such as North America, Europe, and Asia-Pacific.
Global Degarelix Market Overview
The Degarelix market is primarily driven by the rising global prevalence of prostate cancer and the increasing adoption of androgen deprivation therapy (ADT) as a standard treatment for hormone-sensitive and advanced prostate cancer. Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to suppress testosterone levels, which play a key role in the growth and progression of prostate tumors. By directly blocking GnRH receptors in the pituitary gland, the drug rapidly reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a fast and sustained decrease in testosterone production and slowing cancer progression.
The market has gained traction due to the clinical advantages of degarelix compared with traditional GnRH agonists used in prostate cancer therapy. Unlike GnRH agonists, degarelix does not cause an initial testosterone surge (also known as "tumor flare"), which can worsen symptoms in patients with advanced disease. This rapid suppression of testosterone without flare has made degarelix an important therapeutic option in hormonal treatment regimens, particularly for patients with metastatic or advanced hormone-dependent prostate cancer. Its effectiveness in reducing prostate-specific antigen (PSA) levels and delaying disease progression further supports its growing clinical adoption.
In addition, increasing awareness of early cancer diagnosis, expanding oncology treatment infrastructure, and ongoing research in hormonal therapies are contributing to the expansion of the degarelix market. Pharmaceutical companies are also focusing on improving formulations, optimizing dosing regimens, and expanding access in emerging healthcare markets. However, the market faces competition from other androgen deprivation therapies, including newer oral GnRH antagonists and established LHRH agonists, which may influence treatment preferences. Despite these challenges, continued advancements in prostate cancer therapeutics and the growing demand for effective hormone-suppressing treatments are expected to support steady market growth in the coming years.
Global Degarelix Market: Segmentation Analysis
The Global Degarelix Market is segmented based on Indication, Dosage Form, Distribution Channel, and Geography.
Global Degarelix Market by Indication
Prostate Cancer
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Hormone-Sensitive Prostate Cancer
Based on Indication, The Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) segment is expected to be the fastest-growing in the Degarelix market. Growth is driven by the increasing number of prostate cancer patients progressing to the castration-resistant stage and the rising demand for advanced hormone-based therapies to delay metastasis and improve survival outcomes.
Global Degarelix Market by Dosage Form
Injection
Subcutaneous Injection
Based on Dosage Form, The Subcutaneous Injection segment is expected to be the fastest-growing dosage form in the Degarelix market. Degarelix is primarily designed and clinically administered as a subcutaneous injection in the abdominal region, enabling rapid testosterone suppression and sustained drug release with monthly dosing.
Global Degarelix Market by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on Distribution Channel, In the Degarelix Market, the Online Pharmacies segment is expected to be the fastest-growing distribution channel. The growth is driven by increasing adoption of digital health platforms, rising internet penetration, and the convenience of home delivery and online prescription services for chronic disease medications.
Global Degarelix Market by Geography
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Based on Geography, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. The Asia-Pacific (APAC) region is expected to be the fastest-growing segment in the Degarelix market. Growth is driven by the rising prevalence of prostate cancer, increasing aging population, and expanding access to oncology treatments in countries such as China, India, and Japan. Additionally, improving healthcare infrastructure, higher healthcare spending, and growing awareness of advanced hormone therapies are accelerating the adoption of Degarelix in the region.
Global Degarelix Market Competitive Landscape
The Global Degarelix Market is highly fragmented with the presence of a large number of players. Some of the major companies include Ferring Pharmaceuticals, Hybio Pharmaceutical Co., Ltd., Suzhou Tianma Pharmaceutical Group, Aurobindo Pharma Limited, Auro Peptides Limited, BDR Lifesciences, Apino Pharma Co., Ltd., PolyPeptide Group, Shenzhen JYMed Technology Co., Ltd., Zhejiang Supor Pharmaceuticals Co., Ltd., among others.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 MARKET DEFINITION
- 1.2 MARKET SEGMENTATION
- 1.3 RESEARCH TIMELINES
- 1.4 ASSUMPTIONS
- 1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
- 2.1 DATA MINING
- 2.2 SECONDARY RESEARCH
- 2.3 PRIMARY RESEARCH
- 2.4 SUBJECT MATTER EXPERT ADVICE
- 2.5 QUALITY CHECK
- 2.6 FINAL REVIEW
- 2.7 DATA TRIANGULATION
- 2.8 BOTTOM-UP APPROACH
- 2.9 TOP-DOWN APPROACH
- 2.10 RESEARCH FLOW
- 2.11 DATA DISTRIBUTION CHANNEL
3 EXECUTIVE SUMMARY
- 3.1 GLOBAL DEGARELIX MARKETOVERVIEW
- 3.2 GLOBAL DEGARELIX MARKETESTIMATES AND FORECAST (USD BILLION)
- 3.3 GLOBAL DEGARELIX MARKETECOLOGY MAPPING
- 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
- 3.5 GLOBAL DEGARELIX MARKETABSOLUTE MARKET OPPORTUNITY
- 3.6 GLOBAL DEGARELIX MARKETATTRACTIVENESS ANALYSIS, BY REGION
- 3.7 GLOBAL DEGARELIX MARKETATTRACTIVENESS ANALYSIS, BY INDICATION
- 3.8 GLOBAL DEGARELIX MARKETATTRACTIVENESS ANALYSIS, BY DOSAGE FORM
- 3.9 GLOBAL DEGARELIX MARKETATTRACTIVENESS ANALYSIS, BY DISTRIBUTION CHANNEL
- 3.10 GLOBAL DEGARELIX MARKETGEOGRAPHICAL ANALYSIS (CAGR %)
- 3.11 GLOBAL DEGARELIX MARKET, BY INDICATION (USD BILLION)
- 3.12 GLOBAL DEGARELIX MARKET, BY DOSAGE FORM (USD BILLION)
- 3.13 GLOBAL DEGARELIX MARKET, BY DISTRIBUTION CHANNEL (USD BILLION)
- 3.14 GLOBAL DEGARELIX MARKET, BY GEOGRAPHY (USD BILLION)
- 3.15 FUTURE MARKET OPPORTUNITIES
4 MARKET OUTLOOK
- 4.1 GLOBAL DEGARELIX MARKETEVOLUTION
- 4.2 GLOBAL DEGARELIX MARKETOUTLOOK
- 4.3 MARKET DRIVERS
- 4.4 MARKET RESTRAINTS
- 4.5 MARKET TRENDS
- 4.6 MARKET OPPORTUNITY
- 4.7 PORTER'S FIVE FORCES ANALYSIS
- 4.7.1 THREAT OF NEW ENTRANTS
- 4.7.2 BARGAINING POWER OF SUPPLIERS
- 4.7.3 BARGAINING POWER OF BUYERS
- 4.7.4 THREAT OF SUBSTITUTE INDICATIONS
- 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
- 4.8 VALUE CHAIN ANALYSIS
- 4.9 PRICING ANALYSIS
- 4.10 MACROECONOMIC ANALYSIS
5 MARKET, BY INDICATION
- 5.1 OVERVIEW
- 5.2 GLOBAL DEGARELIX MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY INDICATION
- 5.3 PROSTATE CANCER
- 5.4 NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
- 5.5 HORMONE-SENSITIVE PROSTATE CANCER
6 MARKET, BY DOSAGE FORM
- 6.1 OVERVIEW
- 6.2 GLOBAL DEGARELIX MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DOSAGE FORM
- 6.3 INJECTION
- 6.4 SUBCUTANEOUS INJECTION
7 MARKET, BY DISTRIBUTION CHANNEL
- 7.1 OVERVIEW
- 7.2 GLOBAL DEGARELIX MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY DISTRIBUTION CHANNEL
- 7.3 HOSPITAL PHARMACIES
- 7.4 RETAIL PHARMACIES
- 7.5 ONLINE PHARMACIES
8 MARKET, BY GEOGRAPHY
- 8.1 OVERVIEW
- 8.2 NORTH AMERICA
- 8.2.1 U.S.
- 8.2.2 CANADA
- 8.2.3 MEXICO
- 8.3 EUROPE
- 8.3.1 GERMANY
- 8.3.2 U.K.
- 8.3.3 FRANCE
- 8.3.4 ITALY
- 8.3.5 SPAIN
- 8.3.6 REST OF EUROPE
- 8.4 ASIA PACIFIC
- 8.4.1 CHINA
- 8.4.2 JAPAN
- 8.4.3 INDIA
- 8.4.4 REST OF ASIA PACIFIC
- 8.5 LATIN AMERICA
- 8.5.1 BRAZIL
- 8.5.2 ARGENTINA
- 8.5.3 REST OF LATIN AMERICA
- 8.6 MIDDLE EAST AND AFRICA
- 8.6.1 UAE
- 8.6.2 SAUDI ARABIA
- 8.6.3 SOUTH AFRICA
- 8.6.4 REST OF MIDDLE EAST AND AFRICA
9 COMPETITIVE LANDSCAPE
- 9.1 OVERVIEW
- 9.2 KEY DEVELOPMENT STRATEGIES
- 9.3 COMPANY REGIONAL FOOTPRINT
- 9.4 ACE MATRIX
- 9.4.1 ACTIVE
- 9.42 CUTTING EDGE
- 9.4.3 EMERGING
- 9.4.4 INNOVATORS
10 COMPANY PROFILES
- 10.1 OVERVIEW
- 10.2 FERRING PHARMACEUTICALS
- 10.3 HYBIO PHARMACEUTICAL CO., LTD
- 10.4 SUZHOU TIANMA PHARMACEUTICAL GROUP
- 10.5 AUROBINDO PHARMA LIMITED
- 10.6 AURO PEPTIDES LIMITED
- 10.7 BDR LIFESCIENCES
- 10.8 APINO PHARMA CO., LTD
- 10.9 POLYPEPTIDE GROUP
- 10.10 SHENZHEN JYMED TECHNOLOGY CO., LTD
- 10.11 SHENZHEN JYMED TECHNOLOGY CO., LTD., ZHEJIANG
(주말 및 공휴일 제외)
